These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

218 related articles for article (PubMed ID: 25212606)

  • 1. A phase I study of continuous oral dosing of OSI-906, a dual inhibitor of insulin-like growth factor-1 and insulin receptors, in patients with advanced solid tumors.
    Puzanov I; Lindsay CR; Goff L; Sosman J; Gilbert J; Berlin J; Poondru S; Simantov R; Gedrich R; Stephens A; Chan E; Evans TR
    Clin Cancer Res; 2015 Feb; 21(4):701-11. PubMed ID: 25212606
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Phase I study of intermittent oral dosing of the insulin-like growth factor-1 and insulin receptors inhibitor OSI-906 in patients with advanced solid tumors.
    Jones RL; Kim ES; Nava-Parada P; Alam S; Johnson FM; Stephens AW; Simantov R; Poondru S; Gedrich R; Lippman SM; Kaye SB; Carden CP
    Clin Cancer Res; 2015 Feb; 21(4):693-700. PubMed ID: 25208878
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Phase I Dose-Escalation Study of Linsitinib (OSI-906) and Erlotinib in Patients with Advanced Solid Tumors.
    Macaulay VM; Middleton MR; Eckhardt SG; Rudin CM; Juergens RA; Gedrich R; Gogov S; McCarthy S; Poondru S; Stephens AW; Gadgeel SM
    Clin Cancer Res; 2016 Jun; 22(12):2897-907. PubMed ID: 26831715
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Phase I and pharmacologic study of OSI-774, an epidermal growth factor receptor tyrosine kinase inhibitor, in patients with advanced solid malignancies.
    Hidalgo M; Siu LL; Nemunaitis J; Rizzo J; Hammond LA; Takimoto C; Eckhardt SG; Tolcher A; Britten CD; Denis L; Ferrante K; Von Hoff DD; Silberman S; Rowinsky EK
    J Clin Oncol; 2001 Jul; 19(13):3267-79. PubMed ID: 11432895
    [TBL] [Abstract][Full Text] [Related]  

  • 5. First-in-human phase I trial of two schedules of OSI-930, a novel multikinase inhibitor, incorporating translational proof-of-mechanism studies.
    Yap TA; Arkenau HT; Camidge DR; George S; Serkova NJ; Gwyther SJ; Spratlin JL; Lal R; Spicer J; Desouza NM; Leach MO; Chick J; Poondru S; Boinpally R; Gedrich R; Brock K; Stephens A; Eckhardt SG; Kaye SB; Demetri G; Scurr M
    Clin Cancer Res; 2013 Feb; 19(4):909-19. PubMed ID: 23403628
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Debio0932, a second-generation oral heat shock protein (HSP) inhibitor, in patients with advanced cancer-results of a first-in-man dose-escalation study with a fixed-dose extension phase.
    Isambert N; Delord JP; Soria JC; Hollebecque A; Gomez-Roca C; Purcea D; Rouits E; Belli R; Fumoleau P
    Ann Oncol; 2015 May; 26(5):1005-1011. PubMed ID: 25646368
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Phase I and biomarker study of OPB-51602, a novel signal transducer and activator of transcription (STAT) 3 inhibitor, in patients with refractory solid malignancies.
    Wong AL; Soo RA; Tan DS; Lee SC; Lim JS; Marban PC; Kong LR; Lee YJ; Wang LZ; Thuya WL; Soong R; Yee MQ; Chin TM; Cordero MT; Asuncion BR; Pang B; Pervaiz S; Hirpara JL; Sinha A; Xu WW; Yuasa M; Tsunoda T; Motoyama M; Yamauchi T; Goh BC
    Ann Oncol; 2015 May; 26(5):998-1005. PubMed ID: 25609248
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Phase I dose-escalation study of capmatinib (INC280) in Japanese patients with advanced solid tumors.
    Esaki T; Hirai F; Makiyama A; Seto T; Bando H; Naito Y; Yoh K; Ishihara K; Kakizume T; Natsume K; Myers A; Doi T
    Cancer Sci; 2019 Apr; 110(4):1340-1351. PubMed ID: 30724423
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A phase 1 dose-escalation study of checkpoint kinase 1 (CHK1) inhibitor prexasertib in combination with p38 mitogen-activated protein kinase (p38 MAPK) inhibitor ralimetinib in patients with advanced or metastatic cancer.
    Bendell JC; Bischoff HG; Hwang J; Reinhardt HC; Zander T; Wang X; Hynes S; Pitou C; Campbell R; Iversen P; Farrington DL; Bell-McGuinn K; Thomas M
    Invest New Drugs; 2020 Aug; 38(4):1145-1155. PubMed ID: 31707688
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A dose-ranging study of the pharmacokinetics and pharmacodynamics of the selective apoptotic antineoplastic drug (SAAND), OSI-461, in patients with advanced cancer, in the fasted and fed state.
    O'Bryant CL; Lieu CH; Leong S; Boinpally R; Basche M; Gore L; Leonardi K; Schultz MK; Hariharan S; Chow L; Diab S; Gibbs A; Eckhardt SG
    Cancer Chemother Pharmacol; 2009 Feb; 63(3):477-89. PubMed ID: 18509645
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Phase I Trial of First-in-Class ATR Inhibitor M6620 (VX-970) as Monotherapy or in Combination With Carboplatin in Patients With Advanced Solid Tumors.
    Yap TA; O'Carrigan B; Penney MS; Lim JS; Brown JS; de Miguel Luken MJ; Tunariu N; Perez-Lopez R; Rodrigues DN; Riisnaes R; Figueiredo I; Carreira S; Hare B; McDermott K; Khalique S; Williamson CT; Natrajan R; Pettitt SJ; Lord CJ; Banerji U; Pollard J; Lopez J; de Bono JS
    J Clin Oncol; 2020 Sep; 38(27):3195-3204. PubMed ID: 32568634
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Phase 1/1b dose escalation and expansion study of BEZ235, a dual PI3K/mTOR inhibitor, in patients with advanced solid tumors including patients with advanced breast cancer.
    Rodon J; Pérez-Fidalgo A; Krop IE; Burris H; Guerrero-Zotano A; Britten CD; Becerra C; Schellens J; Richards DA; Schuler M; Abu-Khalaf M; Johnson FM; Ranson M; Edenfield J; Silva AP; Hackl W; Quadt C; Demanse D; Duval V; Baselga J
    Cancer Chemother Pharmacol; 2018 Aug; 82(2):285-298. PubMed ID: 29882016
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Evaluation of BGJ398, a Fibroblast Growth Factor Receptor 1-3 Kinase Inhibitor, in Patients With Advanced Solid Tumors Harboring Genetic Alterations in Fibroblast Growth Factor Receptors: Results of a Global Phase I, Dose-Escalation and Dose-Expansion Study.
    Nogova L; Sequist LV; Perez Garcia JM; Andre F; Delord JP; Hidalgo M; Schellens JH; Cassier PA; Camidge DR; Schuler M; Vaishampayan U; Burris H; Tian GG; Campone M; Wainberg ZA; Lim WT; LoRusso P; Shapiro GI; Parker K; Chen X; Choudhury S; Ringeisen F; Graus-Porta D; Porter D; Isaacs R; Buettner R; Wolf J
    J Clin Oncol; 2017 Jan; 35(2):157-165. PubMed ID: 27870574
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Phase 1 study of APTO-253 HCl, an inducer of KLF4, in patients with advanced or metastatic solid tumors.
    Cercek A; Wheler J; Murray PE; Zhou S; Saltz L
    Invest New Drugs; 2015 Oct; 33(5):1086-92. PubMed ID: 26268924
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A first-in-Asian phase 1 study to evaluate safety, pharmacokinetics and clinical activity of VS-6063, a focal adhesion kinase (FAK) inhibitor in Japanese patients with advanced solid tumors.
    Shimizu T; Fukuoka K; Takeda M; Iwasa T; Yoshida T; Horobin J; Keegan M; Vaickus L; Chavan A; Padval M; Nakagawa K
    Cancer Chemother Pharmacol; 2016 May; 77(5):997-1003. PubMed ID: 27025608
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Phase I and pharmacokinetic study of YM155, a small-molecule inhibitor of survivin.
    Tolcher AW; Mita A; Lewis LD; Garrett CR; Till E; Daud AI; Patnaik A; Papadopoulos K; Takimoto C; Bartels P; Keating A; Antonia S
    J Clin Oncol; 2008 Nov; 26(32):5198-203. PubMed ID: 18824702
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Phase I study of the safety, tolerability, and pharmacokinetics of oral CP-868,596, a highly specific platelet-derived growth factor receptor tyrosine kinase inhibitor in patients with advanced cancers.
    Lewis NL; Lewis LD; Eder JP; Reddy NJ; Guo F; Pierce KJ; Olszanski AJ; Cohen RB
    J Clin Oncol; 2009 Nov; 27(31):5262-9. PubMed ID: 19738123
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmacokinetics and tolerability of vandetanib in Chinese patients with solid, malignant tumors: an open-label, phase I, rising multiple-dose study.
    Zhang L; Li S; Zhang Y; Zhan J; Zou BY; Smith R; Martin PD; Jiang Y; Liao H; Guan Z
    Clin Ther; 2011 Mar; 33(3):315-27. PubMed ID: 21600385
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A phase 1 study of the sachet formulation of the oral dual PI3K/mTOR inhibitor BEZ235 given twice daily (BID) in patients with advanced solid tumors.
    Bendell JC; Kurkjian C; Infante JR; Bauer TM; Burris HA; Greco FA; Shih KC; Thompson DS; Lane CM; Finney LH; Jones SF
    Invest New Drugs; 2015 Apr; 33(2):463-71. PubMed ID: 25707361
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Phase I safety, pharmacokinetic, and pharmacodynamic study of SAR245409 (XL765), a novel, orally administered PI3K/mTOR inhibitor in patients with advanced solid tumors.
    Papadopoulos KP; Tabernero J; Markman B; Patnaik A; Tolcher AW; Baselga J; Shi W; Egile C; Ruiz-Soto R; Laird AD; Miles D; Lorusso PM
    Clin Cancer Res; 2014 May; 20(9):2445-56. PubMed ID: 24583798
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.